P61964 (WDR5_HUMAN) Homo sapiens (Human)

WD repeat-containing protein 5 UniProtKBInterProSTRINGInteractive Modelling

334 aa; Sequence (Fasta) ; 52 identical sequences

Available Structures

120 Experimental Structures

DescriptionOligo-stateLigandsStructureRange
Modulating Protein-Protein Interactions with Visible Light Peptide Backbone Switches Heteromer
G2XKQ0;
K;NA;29-334
Assess
WDR5 and Histone H3 Lysine 4 dimethyl complex at 2.1 angstrom Heteromer
P68431;
29-334
Assess
WDR5 in complex with influenza NS1 C-terminal tail Heteromer
P03495;
17×UNX;30-334
Assess
X-ray structure of WDR5-MLL3 Win motif peptide binary complex Heteromer
Q8NEZ4;
31-334
Assess
Crystal structure of WDR5 in complex with the WDR5-interacting motif of MLL2 Heteromer
O14686;
BTB;SO4;31-334
Assess
Crystal structure of the KANSL1-WDR5 complex. Heteromer
Q7Z3B3;
GOL;31-334
Assess
X-ray structure of WDR5-SETd1a Win motif peptide binary complex Heteromer
O15047;
31-334
Assess
Crystal structure of WDR5 in complex with the WDR5-interacting motif of MLL4 Heteromer
Q9UMN6;
31-334
Assess
Crystal structure of human WDR5 in complex with monomethyl H3R2 peptide Heteromer
Q6NXT2;
GOL;SO4;31-334
Assess
X-ray structure of WDR5-MLL1 Win motif peptide binary complex Heteromer
Q03164;
31-334
Assess
Structure of WDR5 bound to MLL1 peptide Heteromer
Q03164;
SO4;31-334
Assess
X-ray structure of WDR5-MLL4 Win motif peptide binary complex Heteromer
Q9UMN6;
31-334
Assess
Crystal structure of WDR5 in complex with the WDR5-interacting motif of SET1A Heteromer
O15047;
31-334
Assess
X-ray structure of WDR5-SETd1b Win motif peptide binary complex Heteromer
Q9UPS6;
31-334
Assess
Crystal structure of WDR5 in complex with MYC MbIIIb peptide Heteromer
P01106;
TRS;EDO;31-334
Assess
WDR5 in complex with unmodified H3K4 peptide Heteromer
Q6P823;
31-334
Assess
X-ray structure of WDR5-MLL2 Win motif peptide binary complex Heteromer
O14686;
31-334
Assess
WDR5 in complex with trimethylated H3K4 peptide Heteromer
Q6P823;
31-334
Assess
WDR5 in complex with monomethylated H3K4 peptide Heteromer
Q6P823;
31-334
Assess
Crystal structure of the KANSL1-WDR5-KANSL2 complex. Heteromer
Q7Z3B3; Q9H9L4;
31-334
Assess
Crystal structure of WDR5 in complex with the WDR5-interacting motif of SET1B Heteromer
Q9UPS6;
31-334
Assess
Crystal structure of WDR5 in complex with the WDR5-interacting motif of MLL3 Heteromer
Q8NEZ4;
31-334
Assess
WDR5 and unmodified Histone H3 complex at 2.25 angstrom Heteromer
P68431;
31-334
Assess
Structural and biochemical insights into MLL1 core complex assembly and regulation. Heteromer
Q03164; Q15291;
31-334
Assess
WDR5 IN COMPLEX WITH AN RBBP5 PEPTIDE RECRUITED TO NOVEL SITE Heteromer
P61965; Q8BX09;
GOL;31-334
Assess
Crystal structure of WDR5-Mb(S4) monobody complex Heteromer
31-334
Assess
Symmetric Dimethylation of H3 Arginine 2 is a Novel Histone Mark that Supports Euchromatin Maintena… Heteromer
P68431;
32-334
Assess
WDR5 IN COMPLEX WITH AN RBBP5 PEPTIDE AND HISTONE H3 PEPTIDE Heteromer
P61965; P68433; Q8BX09;
GOL;32-334
Assess
Crystal structure of WDR5 in complex with the WIN peptide of PDPK1 Heteromer
O15530;
30-332
Assess
Cryo-EM structure of MLL1 core complex bound to the nucleosome Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291; Q9C005; Q9UBL3;
SAH;ZN;32-334
Assess
Cryo-EM structure of MLL1 in complex with RbBP5 and WDR5 bound to the nucleosome Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291;
SAH;ZN;32-334
Assess
Cryo-EM structure of MLL1 in complex with RbBP5, WDR5, SET1, and ASH2L bound to the nucleosome (Cla… Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3;
32-334
Assess
Cryo-EM structure of MLL1 in complex with RbBP5, WDR5, SET1, and ASH2L bound to the nucleosome (Cla… Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3;
32-334
Assess
Cryo-EM structure of MLL1 in complex with RbBP5, WDR5, SET1, and ASH2L bound to the nucleosome (Cla… Heteromer
P02281; P62799; P84233; Q03164; Q15291; Q6AZJ8; Q9UBL3;
32-334
Assess
Structural basis of WDR5-MLL interaction Heteromer
Q03164;
SO4;33-332
Assess
Cryo-EM structure of human MLL3-ubNCP complex (4.0 angstrom) Heteromer
P02281; P06897; P62799; P62979; P84233; Q15291; Q8NEZ4; Q9UBL3;
ZN;33-332
Assess
Cryo-EM structure of human MLL1-NCP complex, binding mode1 Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3;
SAH;ZN;LYS;GLN;33-332
Assess
Cryo-EM structure of human MLL1-NCP complex, binding mode2 Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3;
SAH;ZN;33-332
Assess
Cryo-EM structure of human MLL1-ubNCP complex (3.2 angstrom) Heteromer
P02281; P06897; P62799; P62979; P84233; Q03164; Q15291; Q9UBL3;
SAH;ZN;LYS;GLN;33-332
Assess
Cryo-EM structure of human MLL1-ubNCP complex (4.0 angstrom) Heteromer
P02281; P06897; P62799; P62979; P84233; Q03164; Q15291; Q9UBL3;
SAH;ZN;33-332
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC intera…homo-2-merQF1;31-334
Assess
Characterization of Peptide Ligands Against WDR5 Isolated Using Phage Display Techniquehomo-2-mer31-334
Assess
Structure of wdr5monomerCL;11-334
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the WDR5-MYC inter…monomerQBS;SO4;22-334
Assess
Discovery and Structure-Based optimization of potent and selective WDR5 inhibitors containing a dih…monomerQ41;23-334
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomerQ0Y;24-334
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomerQ1M;24-334
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomerQ1J;24-334
Assess
Crystal structure of human WDR5 in complex with compound 9emonomer5MO;GOL;CL;EDO; 14×UNX;24-334
Assess
WDR5delta23monomerSO4;24-334
Assess
Crystal structure of human WD repeat domain 5 with compound MM-401monomer24-334
Assess
Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinitymonomerHLP;28-334
Assess
Crystal structure of human WD repeat domain 5 with compound MM-402monomer28-334
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the WDR5-MYC inter…monomerQBM;30-334
Assess
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…monomerDMS;G2V;30-334
Assess
Crystal structure of human WD REPEAT DOMAIN 5 in complex with 2-chloro-4-fluoro-3-methyl-N-[2-(4-me…monomerIA9;EDO; 24×UNX;30-334
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the WDR5-MYC inter…monomerQBP;30-334
Assess
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…monomerG2D;30-334
Assess
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…monomerNA;FZM;30-334
Assess
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complexmonomer30-334
Assess
WDR5 in complex with a WIN site inhibitormonomerHHM;SO4;DMS;30-334
Assess
Structural basis for the specific recognition of methylated histone H3 lysine 4 by the WD-40 protei…monomer29-333
Assess
WDR5 in complex with Myc site fragment inhibitormonomerQ8D;31-334
Assess
WDR5 in complex with Myc site fragment inhibitormonomerQ8G;31-334
Assess
Crystal structure of human WDR5 in complex with compound OICR-9429monomer35Q;UNX;31-334
Assess
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complexmonomer31-334
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC intera…monomerQ8S;31-334
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomerQ0M;31-334
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomerQ1P;Q1S;31-334
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomerQ1G;31-334
Assess
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…monomerG1Y;DMS;31-334
Assess
Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinitymonomerHLS;SO4;31-334
Assess
Crystal structure of WDR5 in complex with a H3Q5ser peptidemonomerSRO;31-334
Assess
Crystal structure of WDR5 in complex with H3K4me3Q5ser peptidemonomerGOL;EDO;SRO;31-334
Assess
WDR5delta23 bound to (2-(3-phenylpropyl)-1H-imidazol-4-yl)methanolmonomerOGY;CL;31-334
Assess
WDR5delta23 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)acetamidemonomerSO4;OH7;CL;31-334
Assess
Crystal structure of human WDR5 in complex with symmetric dimethyl-L-argininemonomerSO4;GOL;2MR;31-334
Assess
Crystal structure of human WDR5 in complex with monomethyl L-argininemonomerSO4;GOL;NMM;31-334
Assess
WDR5delta23 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)benzamidemonomerOH1;31-334
Assess
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complexmonomer31-334
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomerQ0S;31-334
Assess
Crystal structure of human WDR5 in complex with compound 9omonomer5MN;EDO; 11×UNX;31-334
Assess
Crystal structure of WDR5, WD repeat domain 5 in complex with compound SGC-DS-MT-0345monomer37F;CL;EDO;UNX;31-334
Assess
Crystal structure of human WDR5 in complex with compound 9dmonomer5MQ;EDO;UNX;31-334
Assess
Crystal structure of human WDR5 in complex with compound 9hmonomer5ML;GOL;CL;EDO; 13×UNX;31-334
Assess
Crystal structure of human WD repeat domain 5 with compoundmonomer0BW;EDO;CL;SO4; 17×UNX;31-334
Assess
Crystal structure of human WD repeat domain 5 with compoundmonomerNP7;EDO;UNX;31-334
Assess
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complexmonomer31-334
Assess
Structural basis for the specific recognition of methylated histone H3 lysine 4 by the WD-40 protei…monomer30-333
Assess
WDR5 in Complex with Dimethylated H3K4 Peptidemonomer31-334
Assess
WDR5 in complex with a WIN site inhibitormonomerHH7;DMS;SO4;31-334
Assess
Crystal structure of human WDR5 in complex with L-argininemonomerARG;SO4;GOL;31-334
Assess
WDR5 in complex with MLL Win motif peptidomimeticmonomer31-334
Assess
WDR5delta23 bound to (2-butyl-1H-imidazol-4-yl)methanolmonomerOHJ;31-334
Assess
Crystal structure of WDR5 mutant (S62A)monomer31-334
Assess
Crystal structure of WDR5 mutant (W330F)monomer31-334
Assess
Crystal structure of WDR5 mutant (W330Y)monomer31-334
Assess
Crystal structure of human WD repeat domain 5 with compound MM-102monomer31-334
Assess
Crystal structure of human WD repeat domain 5 with compound MM-101monomer31-334
Assess
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…monomerHLM;32-334
Assess
Crystal of WDR5 (apo-form)monomer32-334
Assess
WDR5delta32 bound to peptidomimeticmonomerOK4;SO4;32-334
Assess
WDR5delta32 bound to N-(4-(4-(hydroxymethyl)-1H-imidazol-2-yl)butyl)acrylamidemonomerOJP;SO4;32-334
Assess
Crystal structure of WDR5/histone H3 complexmonomer32-334
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC intera…monomerQ8M;32-334
Assess
WDR5delta32 bound to (2-methyl-1H-imidazol-4-yl)methanolmonomerOHG;SO4;32-334
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC intera…monomerQ8P;32-334
Assess
Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinitymonomerHLJ;32-334
Assess
Fine-tuning the stimulation of MLL1 methyltransferase activity by a histone H3 based peptide mimeticmonomer32-334
Assess
WDR5delta32 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)-2-phenylacetamidemonomerOJG;SO4;32-334
Assess
WDR5delta32 bound to ethyl 3-(4-(hydroxymethyl)-1H-imidazol-2-yl)propanoatemonomerOJM;SO4;EDO;32-334
Assess
WDR5delta32 bound to methyl benzyl(4-(4-(hydroxymethyl)-1H-imidazol-2-yl)butyl)carbamatemonomerSO4;OJJ;32-334
Assess
Crystal structure of human WDR5monomer32-334
Assess
WDR5delta32 bound to benzyl (4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)carbamatemonomerOHV;SO4;32-334
Assess
WD repeat-containing protein 5 complexed with N-[(3,5-dimethoxyphenyl)methyl]-4'-fluoro-5-{[(2E)-2-…monomerQ6S;32-334
Assess
WDR5delta32 bound to methyl (4-(4-(hydroxymethyl)-1H-imidazol-2-yl)butyl)carbamatemonomerOGM;SO4;32-334
Assess
WDR5delta32 bound to (2-(3-methoxy-3-phenylpropyl)-1H-imidazol-4-yl)methanolmonomerOH4;PEG;32-334
Assess
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…monomerG2J;SO4;DMS;31-332
Assess
Modulation of MLL1 Methyltransferase Activitymonomer7DC;33-332
Assess
Modulation of MLL1 Methyltransferase Activitymonomer7DU;33-332
Assess

1 Homology model

Oligo-stateLigandsQMEANDisCoTemplateRangeSeq id (%)
monomer0.902gnq.1.A11-334
100.00
Assess

Alignments